Manufacturing problems at Akorn Inc.’s New Jersey plant “pose a risk to patients,” U.S. regulators have warned the embattled generic-drug...
We have updated our privacy policy to be more clear and meet the new requirements of the GDPR. By continuing to use our site, you accept our revised Privacy Policy.
